Cargando…

Regenerative Medicine for the Treatment of Ischemic Heart Disease; Status and Future Perspectives

Cardiovascular disease is now the leading cause of adult death in the world. According to new estimates from the World Health Organization, myocardial infarction (MI) is responsible for four out of every five deaths due to cardiovascular disease. Conventional treatments of MI are taking aspirin and...

Descripción completa

Detalles Bibliográficos
Autores principales: Arjmand, Babak, Abedi, Mina, Arabi, Maryam, Alavi-Moghadam, Sepideh, Rezaei-Tavirani, Mostafa, Hadavandkhani, Mahdieh, Tayanloo-Beik, Akram, Kordi, Ramin, Roudsari, Peyvand Parhizkar, Larijani, Bagher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461329/
https://www.ncbi.nlm.nih.gov/pubmed/34568321
http://dx.doi.org/10.3389/fcell.2021.704903
_version_ 1784571954457477120
author Arjmand, Babak
Abedi, Mina
Arabi, Maryam
Alavi-Moghadam, Sepideh
Rezaei-Tavirani, Mostafa
Hadavandkhani, Mahdieh
Tayanloo-Beik, Akram
Kordi, Ramin
Roudsari, Peyvand Parhizkar
Larijani, Bagher
author_facet Arjmand, Babak
Abedi, Mina
Arabi, Maryam
Alavi-Moghadam, Sepideh
Rezaei-Tavirani, Mostafa
Hadavandkhani, Mahdieh
Tayanloo-Beik, Akram
Kordi, Ramin
Roudsari, Peyvand Parhizkar
Larijani, Bagher
author_sort Arjmand, Babak
collection PubMed
description Cardiovascular disease is now the leading cause of adult death in the world. According to new estimates from the World Health Organization, myocardial infarction (MI) is responsible for four out of every five deaths due to cardiovascular disease. Conventional treatments of MI are taking aspirin and nitroglycerin as intermediate treatments and injecting antithrombotic agents within the first 3 h after MI. Coronary artery bypass grafting and percutaneous coronary intervention are the most common long term treatments. Since none of these interventions will fully regenerate the infarcted myocardium, there is value in pursuing more innovative therapeutic approaches. Regenerative medicine is an innovative interdisciplinary method for rebuilding, replacing, or repairing the missed part of different organs in the body, as similar as possible to the primary structure. In recent years, regenerative medicine has been widely utilized as a treatment for ischemic heart disease (one of the most fatal factors around the world) to repair the lost part of the heart by using stem cells. Here, the development of mesenchymal stem cells causes a breakthrough in the treatment of different cardiovascular diseases. They are easily obtainable from different sources, and expanded and enriched easily, with no need for immunosuppressing agents before transplantation, and fewer possibilities of genetic abnormality accompany them through multiple passages. The production of new cardiomyocytes can result from the transplantation of different types of stem cells. Accordingly, due to its remarkable benefits, stem cell therapy has received attention in recent years as it provides a drug-free and surgical treatment for patients and encourages a more safe and feasible cardiac repair. Although different clinical trials have reported on the promising benefits of stem cell therapy, there is still uncertainty about its mechanism of action. It is important to conduct different preclinical and clinical studies to explore the exact mechanism of action of the cells. After reviewing the pathophysiology of MI, this study addresses the role of tissue regeneration using various materials, including different types of stem cells. It proves some appropriate data about the importance of ethical problems, which leads to future perspectives on this scientific method.
format Online
Article
Text
id pubmed-8461329
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-84613292021-09-25 Regenerative Medicine for the Treatment of Ischemic Heart Disease; Status and Future Perspectives Arjmand, Babak Abedi, Mina Arabi, Maryam Alavi-Moghadam, Sepideh Rezaei-Tavirani, Mostafa Hadavandkhani, Mahdieh Tayanloo-Beik, Akram Kordi, Ramin Roudsari, Peyvand Parhizkar Larijani, Bagher Front Cell Dev Biol Cell and Developmental Biology Cardiovascular disease is now the leading cause of adult death in the world. According to new estimates from the World Health Organization, myocardial infarction (MI) is responsible for four out of every five deaths due to cardiovascular disease. Conventional treatments of MI are taking aspirin and nitroglycerin as intermediate treatments and injecting antithrombotic agents within the first 3 h after MI. Coronary artery bypass grafting and percutaneous coronary intervention are the most common long term treatments. Since none of these interventions will fully regenerate the infarcted myocardium, there is value in pursuing more innovative therapeutic approaches. Regenerative medicine is an innovative interdisciplinary method for rebuilding, replacing, or repairing the missed part of different organs in the body, as similar as possible to the primary structure. In recent years, regenerative medicine has been widely utilized as a treatment for ischemic heart disease (one of the most fatal factors around the world) to repair the lost part of the heart by using stem cells. Here, the development of mesenchymal stem cells causes a breakthrough in the treatment of different cardiovascular diseases. They are easily obtainable from different sources, and expanded and enriched easily, with no need for immunosuppressing agents before transplantation, and fewer possibilities of genetic abnormality accompany them through multiple passages. The production of new cardiomyocytes can result from the transplantation of different types of stem cells. Accordingly, due to its remarkable benefits, stem cell therapy has received attention in recent years as it provides a drug-free and surgical treatment for patients and encourages a more safe and feasible cardiac repair. Although different clinical trials have reported on the promising benefits of stem cell therapy, there is still uncertainty about its mechanism of action. It is important to conduct different preclinical and clinical studies to explore the exact mechanism of action of the cells. After reviewing the pathophysiology of MI, this study addresses the role of tissue regeneration using various materials, including different types of stem cells. It proves some appropriate data about the importance of ethical problems, which leads to future perspectives on this scientific method. Frontiers Media S.A. 2021-09-10 /pmc/articles/PMC8461329/ /pubmed/34568321 http://dx.doi.org/10.3389/fcell.2021.704903 Text en Copyright © 2021 Arjmand, Abedi, Arabi, Alavi-Moghadam, Rezaei-Tavirani, Hadavandkhani, Tayanloo-Beik, Kordi, Roudsari and Larijani. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cell and Developmental Biology
Arjmand, Babak
Abedi, Mina
Arabi, Maryam
Alavi-Moghadam, Sepideh
Rezaei-Tavirani, Mostafa
Hadavandkhani, Mahdieh
Tayanloo-Beik, Akram
Kordi, Ramin
Roudsari, Peyvand Parhizkar
Larijani, Bagher
Regenerative Medicine for the Treatment of Ischemic Heart Disease; Status and Future Perspectives
title Regenerative Medicine for the Treatment of Ischemic Heart Disease; Status and Future Perspectives
title_full Regenerative Medicine for the Treatment of Ischemic Heart Disease; Status and Future Perspectives
title_fullStr Regenerative Medicine for the Treatment of Ischemic Heart Disease; Status and Future Perspectives
title_full_unstemmed Regenerative Medicine for the Treatment of Ischemic Heart Disease; Status and Future Perspectives
title_short Regenerative Medicine for the Treatment of Ischemic Heart Disease; Status and Future Perspectives
title_sort regenerative medicine for the treatment of ischemic heart disease; status and future perspectives
topic Cell and Developmental Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461329/
https://www.ncbi.nlm.nih.gov/pubmed/34568321
http://dx.doi.org/10.3389/fcell.2021.704903
work_keys_str_mv AT arjmandbabak regenerativemedicineforthetreatmentofischemicheartdiseasestatusandfutureperspectives
AT abedimina regenerativemedicineforthetreatmentofischemicheartdiseasestatusandfutureperspectives
AT arabimaryam regenerativemedicineforthetreatmentofischemicheartdiseasestatusandfutureperspectives
AT alavimoghadamsepideh regenerativemedicineforthetreatmentofischemicheartdiseasestatusandfutureperspectives
AT rezaeitaviranimostafa regenerativemedicineforthetreatmentofischemicheartdiseasestatusandfutureperspectives
AT hadavandkhanimahdieh regenerativemedicineforthetreatmentofischemicheartdiseasestatusandfutureperspectives
AT tayanloobeikakram regenerativemedicineforthetreatmentofischemicheartdiseasestatusandfutureperspectives
AT kordiramin regenerativemedicineforthetreatmentofischemicheartdiseasestatusandfutureperspectives
AT roudsaripeyvandparhizkar regenerativemedicineforthetreatmentofischemicheartdiseasestatusandfutureperspectives
AT larijanibagher regenerativemedicineforthetreatmentofischemicheartdiseasestatusandfutureperspectives